Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HyperaHYPMY -1.34%87 Days Payable is 112.56 as of Mar. 2026, which is 13% below its 10-year median of 129.16. GuruFocus rates HYPMY with a GF Score™ of 87/100 and a GF Value™ of $6.20 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 927 Drug Manufacturers companies, Hypera ranks better than 58.36% on this metric.
Hypera's average Accounts Payable for the
three
months ended in Mar. 2026 was $190 Mil. Hypera's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $154 Mil.
Hence, Hypera's Days Payable for the
three
months ended in Mar. 2026 was 112.56.
The historical rank and industry rank for Hypera's Days Payable or its related term are showing as below:
HYPMY'
s Days Payable Range Over the Past 10 Years
Min: 104.58 Med: 129.16 Max: 161.48
Current: 104.58
During the past 13 years, Hypera's highest Days Payable was 161.48. The lowest was 104.58. And the median was 129.16.
HYPMY's Days Payable is ranked better than 58.36% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs HYPMY: 104.58
Hypera's Days Payable
declined
from Mar. 2025 (143.69) to Mar. 2026 (112.56).
It may suggest that Hyperaaccelerated paying its suppliers.
Hypera Days Payable Related Terms
Hypera Days Payable Historical Data
* Premium members only.
The historical data trend for Hypera's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypera Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hypera's Days Payable distribution charts can be found below:
* The bar in red indicates where Hypera's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hypera's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hypera (HYPMY) has a Days Payable of 112.56 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hypera and its competitors. This is 13% below median its historical median of 129.16. Over the past decade, Hypera's Days Payable has ranged from 104.58 to 161.48. According to the industry distribution chart, Hypera ranks #386 out of 927 companies in the Drug Manufacturers industry, placing it in the top 41.6%.
Is Hypera's Days Payable too high?
Hypera's current Days Payable of 112.56 is 13% below median its 10-year median of 129.16. Over the past 10 years, this metric has ranged from a low of 104.58 to a high of 161.48. The Drug Manufacturers industry median Days Payable is 90.38. Hypera's value of 112.56 is 24.5% above this industry median. Based on the distribution chart, Hypera ranks #386 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hypera has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hypera's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hypera ranks #386 out of 927 companies for Days Payable. This puts Hypera in the upper half of its industry. The industry median Days Payable is 90.38. Hypera's value of 112.56 is 24.5% above this benchmark. Historically, Hypera's own Days Payable has ranged from 104.58 to 161.48 over the past decade. While the company's 10-year median is 129.16 vs. the industry median of 90.38, Hypera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hypera's current Days Payable of 112.56 is 24.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hypera and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypera's current Days Payable is 112.56, which is 13% below median its own 10-year median of 129.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypera stock overvalued right now?
Based on GuruFocus' analysis, Hypera (HYPMY) is currently considered Possible Value Trap. The stock's GF Value™ is $6.20, compared to a current price of $4.06 — trading 34.5% below its estimated fair value. The current Days Payable is 112.56, which is 13% below median its 10-year median of 129.16 and 24.5% above the Drug Manufacturers industry median of 90.38. Hypera's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hypera (HYPMY), the current Days Payable is 112.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hypera (HYPMY) Overvalued in 2026?
Based on GuruFocus' analysis, Hypera stock appears to be undervalued.
The current stock price of $4.06 is trading 34.5% below its estimated GF Value™ of $6.20.
GuruFocus considers Hypera to be Possible Value Trap.
Key valuation signals for HYPMY:
Days Payable: 112.56 (13% below median its 10-year median of 129.16)
GF Value™: $6.20 vs. price of $4.06 (34.5% below fair value)
Industry Position: 24.5% above the Drug Manufacturers median (#386 of 927)
No single metric tells the full story. See the HYPMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hypera SA is a specialty and generic drug manufacturing company. The company operates in the prescription medicines, over-the-counter (OTC) medicines, branded generics, and generics, and skincare segments within the retail pharmaceutical market. The company also has a wide sales and distribution structure. The company's product portfolio includes key brands in Gastroenterology, Pain, Sun Protection, Skin Moisture, and Cleansing within the over-the-counter (OTC) and Skincare segments, as well as new products in Cardiology, Central Nervous System, and Respiratory System within the prescription medicines segment.
87GF Score
Get the complete analysis for HYPMY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYPMY has been successfully added to your 
